January 24, 2018 / 2:40 PM / in 9 months

BRIEF-Novartis generics head sees U.S. price pressure in 2018

Jan 24 (Reuters) - Novartis:

* SANDOZ HEAD SAYS U.S. PRICING PRESSURE TO CONTINUE IN 2018, WILL ABATE AS BIOSIMILARS COME THROUGH IN COMING YEARS

* CEO SAYS CONTINUES TO EXPECT BIOSIMILARS TO BE A MULTI-BILLION DOLLAR BUSINESS, BUT MUST OVERCOME PATENT HURDLES IN UNITED STATES Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below